Summary:
If you suffer from excessive daytime sleepiness due to idiopathic hypersomnia, you may want to consider the Vibrance-3 Study.
Study Purpose:
The Vibrance-3 Study is researching the safety and effectiveness of a once-daily oral investigational study drug and how it may work in adults 18–70 years of age for the potential treatment of excessive daytime sleepiness (EDS) symptoms in adults with idiopathic hypersomnia (IH). The study drug, ALKS 2680, is an orexin-2 receptor agonist, meaning that it is designed to promote wakefulness by activating orexin – a chemical in the brain that helps regulate the sleep/wake cycle.
All participants who qualify will receive the study drug or placebo (a tablet that looks like the study drug but contains no active medicine), as well as study-related procedures and study-related laboratory tests at no cost. Compensation for time and travel may also be available.
Eligibility Criteria:
Eligible participants must:
- Be 18–70 years of age
- Experience excessive daytime sleepiness
- Have a primary diagnosis of IH
- Have a body mass index (BMI) between 18 and 40 kg/m2
- Not have symptoms of IH secondary to another medical condition
- Not have untreated or uncontrolled sleep apnea
Other inclusion and exclusion criteria apply.